The use of LAR as a point-of-care test combined with ISS as a cheap and available alternative to MCP-1 plus ISS enabled determination of patients at high risk for sepsis development who would benefit most from the prophylactic immunomodulatory interventions. This evidence concerns the gene CCL2 and Sepsis.